Screener

Eligibility screening

Autologous CD22 Chimeric Antigen Receptor (CAR) T Cells in w/Recurrent/Refractory B Cell Lymphomas

Sponsored by Stanford UniversityStudy detailsClinicalTrials.gov

1 US site in CA

Before we begin

Who are you filling this out for?

Your answer affects how the questions are phrased.